Metformin is the key factor for elevated plasma GDF-15 levels in type 2 diabetes:a nested, case-control study by  et al.
                                                                    
University of Dundee
Metformin is the key factor for elevated plasma GDF-15 levels in type 2 diabetes
SUMMIT Consortium; Natali, Andrea; Nesti, Lorenzo; Venturi, Elena; Shore, Angela C.; Khan,
Faisel
Published in:
Diabetes, Obesity & Metabolism
DOI:
10.1111/dom.13519
Publication date:
2019
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
SUMMIT Consortium, Natali, A., Nesti, L., Venturi, E., Shore, A. C., Khan, F., ... Nilsson, J. (2019). Metformin is
the key factor for elevated plasma GDF-15 levels in type 2 diabetes: a nested, case-control study. Diabetes,
Obesity & Metabolism, 21(2), 412-416. https://doi.org/10.1111/dom.13519
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 19. Oct. 2019
A
cc
ep
te
d 
A
rti
cl
e
Metformin is the key factor for elevated plasma GDF-15 levels 
in type 2 diabetes: a nested, case-control study 
 
Andrea Natali
1
, Lorenzo Nesti
1
, Elena Venturi
1
, Angela C. Shore
2
,
 
Faisel Khan
3
, Kim 
Gooding
2
, Phillip E. Gates
2
, Helen C Looker
3
, Fiona Dove
3
, Isabel Goncalves
4
, Margaretha 
Persson
4
, Jan Nilsson
4 
on behalf of the SUMMIT consortium. 
 
 
1
Department of Clinical and Experimental Medicine, University of Pisa, Italy; 
2
Diabetes 
and Vascular Medicine, University of Exeter Medical School and NIHR Exeter Clinical 
Research Facility, Exeter, UK; 
3
Division of Molecular & Clinical Medicine, University of 
Dundee, Dundee, UK; and 
4
Department of Clinical Sciences Malmö, Lund University, 
Sweden 
 
 
Address for correspondence:  
Andrea Natali, MD 
Department of Clinical and Experimental Medicine  
University of Pisa 
Via Savi 10, 56126 Pisa, Italy 
E-mail: andrea.natali@med.unipi.it 
 
Coauthors’ contacts: 
lorenzonesti90@gmail.com; eventuri@hotmail.it; A.C.Shore@exeter.ac.uk; 
f.khan@dundee.ac.uk; K.M.Gooding@exeter.ac.uk; phillip.gates@pms.ac.uk; 
h.c.looker@dundee.ac.uk; f.dove@dundee.ac.uk; isabel.goncalves@med.lu.se; 
margaretha.persson@med.lu.se; Jan.Nilsson@med.lu.se. 
 
 
 
 
  
This article is protected by copyright. All rights reserved.
 
 
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which 
may lead to differences between this version and the Version of Record. Please cite this 
article as doi: 10.1111/dom.13519
  
A
cc
ep
te
d 
A
rti
cl
e
Abstract 
Produced as a tissue defence-response to hypoxia and inflammation, Growth Differentiation Factor-15 
(GDF-15) is raised in subjects on metformin treatment. To gain insight into the relationship of GDF-15 
with metformin and major cardiovascular risk factors, we analyzed the data of the SUMMIT cohort 
(n=1,438), a 4 centres, nested, case-control study aiming at verifying whether biomarkers of 
atherosclerosis differ according to the presence of type 2 diabetes and cardiovascular disease. While in 
univariate analysis, major cardiovascular risk factors, with the exception of gender and cholesterol, 
increased similarly and linearly across GDF-15 quartiles, the independent variables associated with 
GDF-15, both in subjects with and without diabetes were age, plasma creatinine, NT-proBNP, diuretic 
use, smoke load, and HbA1c. In subjects with diabetes metformin treatment was associated to a 40% 
rise in GDF-15, which was independent to the other major factors largely explaining their elevated 
GDF-15 levels. The relatively higher GDF-15 bioavailability might contribute to explain the protective 
cardiovascular effects of metformin. 
 
Key words: Growth Differentiation Factor-15, GDF-15, type 2 diabetes, cardiovascular disease, 
metformin.  
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Introduction 
Growth differentiation factor-15 (GDF-15) is a stress protein synthetized by macrophages, 
cardiomyocytes, adipocytes, and endothelial cells 
1
. Expressed in atherosclerotic plaques of carotid and 
coronary arteries, where it co localizes with macrophages, GDF-15 exerts an inhibitory action on 
chemotaxis and apoptosis 
2
; it is also expressed by cardiomyocytes in response to ischemia also 
producing in this tissue a limitation of leukocyte recruitment and apoptosis 
3
. In cardiomyocytes, GDF-
15 expression is also induced by pressure overload with an overall anti-hypertrophic effect 
4
. GDF-15 
has also been proven to protect in human endothelial cells from high glucose-induced apoptosis 
5
.  
Whether circulating GDF-15 plasma levels reflects the adequacy of the protective tissue responses 
to chemical and physical biologic stressors, or rather the severity of tissue damage, is still unclear 
6
. 
Elevated plasma concentrations are found in several conditions characterized by low-grade 
inflammation and accelerated atherosclerosis like type 2 diabetes (T2D), impaired glucose tolerance 
and insulin resistance 
1,6
. Also in patients with heart failure, GDF-15 is significantly upregulated, and 
its plasma concentrations correlate with the severity of the disease and the prognosis 
7
. Although 
elevated GDF-15 plasma levels have been consistently found in T2D, no information is available on 
whether the degree of metabolic control has an impact per se, whether this is due to their higher 
prevalence of cardiovascular and/or kidney diseases, or to a different sensitivity to known major GDF-
15 modulators. Limited is also the information with regard to the effect of the different glucose 
lowering treatments; interestingly, in the ORIGIN trial participants among 237 serum biomarkers the 
only one associated with metformin treatment was GDF-15 
8
. 
In synthesis, despite its anti-apoptotic, anti-hypertrophic, and anti-inflammatory actions, as a 
clinical biomarker GDF-15 appears to reflect the severity of cardiovascular disease (CVD) 
9
 rather than 
the extent of the activation of the protective mechanisms observed in vitro. Still, if metformin is able to 
upregulate GDF-15 circulating levels independently of other factors, this might represent a mechanism 
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through which the drug exerts its effect in terms of cardiovascular disease protection 
10
. For this reason, 
we sought to identify the major determinants of GDF-15 plasma levels separately in subject with and 
without T2D selected to have a wide range of cardiovascular risk and extent of atherosclerotic disease, 
and to evaluate whether metformin treatment influences the impact of these factors.  
 
Materials and Methods 
Study Population  
The volunteers were recruited among the patients and relatives attending the outpatients clinic for 
metabolic diseases or cardiovascular disease within the SUMMIT multicenter study (http://www.imi-
summit.eu) according to the following criteria: a) T2D and clinically manifest CVD,  b) T2D without 
clinical signs of CVD,  c) CVD but no T2D, and subjects with neither CVD nor T2D, in a 2:2:1:1 
proportion. CVD included any coronary, carotid and peripheral event or positive imaging. Exclusion 
criteria included atrial fibrillation, malignancy, severe renal impairment (eGFR<30 ml/min/1.73 m
2
), or 
any chronic inflammatory disease. All subjects were treated according to the usual standards of care. 
The study was approved by the local ethical review boards. 
Analysis of GDF-15 and NT-proBNP in plasma  
Plasma levels of GDF-15 and NT-proBNP were analyzed by the Proximity Extension Assay (PEA) 
technique using the Proseek Multiplex CVD 96x96 reagents kit (Olink Bioscience, Uppsala, Sweden) 
at the Clinical Biomarkers Facility, Science for Life Laboratory, Uppsala. Details of the methods, and 
the GDF-15 calibration curve used to estimate the approximate absolute concentrations from the 
relative quantification units (NPX), are available at http://www.olink.com. 
 Data and Statistical Analysis 
Subjects were divided according to the presence of T2D and quartiles of plasma levels of GDF-15 
were calculated within each group. Differences across quartiles of GDF-15 were investigated using 
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either Chi-squared or Wilcoxon statistics for frequency or continuous values, respectively. p ≤0.05 was 
considered statistically significant. Multiple regression analysis was conducted according to Restricted 
Maximum likelihood (REML) method using a random effect attribute for the variable center. The 
strength of the associations was quantified by the logWorth value.  
 
Results 
Study population 
The study cohort consisted of 1,438 volunteers (937 men and 501 women, 42 to 88 years old), 
recruited at the 4 centers within the SUMMIT multicenter study (with available GDF-15 data); 448 
patients had T2D and clinically manifest CVD, 495 patients had T2D without clinical history or 
evidence of CVD, 238 patients had CVD but no T2D, and 257 subjects had neither CVD nor T2D.  
GDF-15 and clinical data  
Median approximate plasma GDF-15 concentrations were higher in presence of CVD or T2D 
either alone (775 [571-1,000] and 1,000 [736-1,503] pg/L) or in combination (1,290 [903-1,939] pg/L) 
with respect to absence of both diseases (571 [564-775] pg/L, p<0.001 for all comparisons). Across 
quartiles of plasma GDF-15, the concentration values increased 3 folds in non-diabetic and 4 folds in 
T2D (Supplemental Table 1). Higher GDF-15 levels were associated, in a quasi-linear fashion in both 
study groups, with older age, prevalence of hypertension, history or evidence of major atherosclerotic 
cardiovascular disease, smoking exposure, and systolic blood pressure, while neither gender nor BMI 
were different (Supplemental Table 1). With regard to the ongoing treatments, diuretics and RAS 
blockers increased across quartiles in both groups and among the subjects with T2D higher GDF-15 
values were associated also with a lower prevalence of diet only and a larger use of each and all plasma 
lowering drugs (metformin, sulphonylureas, DDP-IV inhibitors and insulin).  
GDF-15 and biochemical parameters 
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Among the biochemical parameters (Supplemental Table 2), GDF-15 was associated in both study 
groups with higher levels of creatinine, NT-proBNP and also HbA1c. On the other hand, we observed 
an inverse trend with total low-density lipoprotein (LDL)- and high-density lipoprotein (HDL)-
cholesterol, which was coupled to higher rates of ongoing statin therapy. No trend was found with 
plasma triglycerides in either group. 
Multivariate analysis  
In Table 1 are shown the variables, among the clinical and the biochemical ones, showing a 
statistically significant and independent relationship with GDF-15 in multivariate analysis, separately 
for subjects with and without T2D and in the whole population (with T2D entered as a dummy 
variable). In subjects without T2D the variables more strongly associated with GDF-15 were, in this 
order: NT-proBNP, age, serum creatinine, smoke load, diuretic use and HbA1c. In patients with T2D 
the strongest association was observed with ongoing metformin treatment followed by serum creatinine, 
NT-proBNP, age, HbA1c, diuretic treatment and smoke load, in this order. In patients with T2D 
assuming metformin (n=644), approximate absolute plasma GDF-15 levels were 2-fold higher than 
nondiabetic subjects (1,226 [858-1,939] vs 665 [515-903] ng/L), while T2D not on metformin  (n=299) 
had 40% higher values (903 [665-1,290] ng/L, p<0.0001 for all comparisons). Within the T2D subjects 
on metformin, the major predictors of GDF-15 were the same as in the T2D subjects not on metformin 
with the exception of HbA1c that lost is statistical significance. The analysis in the whole study cohort 
confirmed that metformin was the most powerful predictor, followed by a set of 3 variables of 
intermediate strength (creatinine, age, and NT-proBNP) and 3 variables of minor strength (smoke load, 
HbA1c, and diuretic use). Independently from the above-mentioned variables, T2D per se had a 
negligible power as a predictor of GDF-15, while presence of clinically manifest CVD did not enter 
into the model.  
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Discussion 
Our data confirm that plasma GDF-15 is raised at the presence of each and all the major risk 
factors for atherosclerotic CVD with the only exception of plasma LDL-cholesterol. Although still 
observed after adjusting for ongoing statin therapy, the achieved LDL-cholesterol levels are likely to 
inversely reflect to the overall cardiovascular risk of the patients. We also confirm 
8
 that metformin use 
is associated with elevated GDF-15 plasma levels and demonstrate that its contribution largely explains 
the consistent finding of increased plasma GDF-15 levels in T2D.  
When all the relevant variables were entered in a multivariate model, actually a similar pattern was 
observed in both study groups and the whole cohort, with NT-proBNP, age and serum creatinine 
emerging as the most powerful predictors (Table 1). The major difference was in the strength of 
metformin in subjects with T2D, which was well above and also independent of any other variable 
being responsible for a 40% rise in GDF-15. Interestingly, HbA1c, though with a smaller effect, was 
associated with higher GDF-15 values in both T2D and non-T2D, and this is a novel finding. Notably, 
this association was lost in the patients on metformin treatment (ß=0.003±0.002) while it was present in 
T2D subjects not on metformin (ß=0.007±0.001), implying that the drug might prevent the fall in GDF-
15 that is expected to occur with the improvement of metabolic control. Noteworthy, the presence of 
CVD does not appear to contribute to the rise in GDF-15 once age, serum creatinine, NT-proBNP and 
metformin use are taken into account. This suggests that GDF-15, rather than reflecting overall 
atherosclerosis, marks the presence of kidney and cardiac damage. As shown in figure 1, the 
relationship between GDF-15 and NT-proBNP is similar in those with or without T2D, but in T2D on 
metformin it is shifted upright. The higher plasma GDF-15 levels for the same degree of cardiac 
dysfunction might explain the reduced myocardial vulnerability to ischemia and remodeling observed 
in experimental studies with metformin treatment 
10
; GDF-15 could be included in the number of 
known mechanisms 
10
 through which metformin produces its beneficial clinical effects.  
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One possible explanation for the association of GDF-15 with metformin treatment, and also with 
HbA1c, could be that this growth factor is also a powerful marker of presence and severity of 
mitochondrial disorders 
11
 and/or hypoxia 
3
. In fact, both metformin and hyperglycemia are known to 
interfere with mitochondrial bioenergetics. Moreover, high glucose in human umbilical endothelial 
cells 
5
 and in HepG2 cells 
12
 is able to promote GDF-15 expression and secretion, and in non-diabetic 
subjects glucose ingestion is associated with an elevation of plasma GDF-15 
13
.  
We confirm that current smoking is associated with elevated GDF-15 
14
, but being the association 
with smoke load stronger than the current smoking status, we suggest that it is chronic damage on 
pulmonary structures 
15
 that result in a persistent GDF-15 upregulation. Similarly, since circulating 
GDF-15 levels are strongly correlated with its intra-renal expression 
16
, we interpret the association 
with plasma creatinine as a reflection of chronic kidney damage.  
We acknowledge that our cohort has peculiar characteristics and therefore we cannot extend our 
conclusion to the general population. However, its enrichment with patients with CVD and risk factors 
offered the opportunity to explore the full range of pathophysiologic variability of the different 
variables related to CVD. Clearly our analysis is cross-sectional and the subjects were treated with an 
intensity that is expected to be proportional to the severity of their diseases. While this might have 
hampered our ability to detect the relevance of GDF-15 in the natural context of each atherosclerosis-
related disease/condition it also represented an opportunity to gain information on real world 
outpatients with regard to residual and unexplained CVD risk.  
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List of abbreviations 
T2D: type 2 diabetes 
CVD: cardiovascular disease 
BMI: body mass index 
GDF-15: Growth Differentiation Factor-15  
HbA1c: glycated hemoglobin 
NT-proBNP: N-terminal pro-brain natriuretic peptide 
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Legends to figures 
 
Figure 1 - Scatterplot of GDF-15 and NT-proBNP values in the non diabetic population (a) and in the 
subject with type 2 diabetes (b) according to whether were on metformin treatment (dark gray symbols) 
or not (light gray symbols). 
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Table 1 - Multivariate predictors of plasma GDF-15 among the clinical characteristics, the 
biochemical variables  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
§ Multiple regression analysis was conducted according to Restricted Maximum likelihood (REML) method with centre 
entered as a random variable, p ≤0.05 was considered statistically significant. ß coefficients are not standardized, the 
strength of the association is provided by the LogWorth value. The dependent variable GDF-15 is expressed in NPX units 
that approximates the log transformed value of plasma concentration. Due to sparse missing values the models were run in 
482 subjects without diabetes, 892 subjects with type 2 diabetes and in 1,374 subjects in the whole study group. 
 
 
 
Variable (n) LogWorth ß Statistics 
§
 
No diabetes  
NT-proBNP (AU) 11.5 0.169 <0.0001 
Age (yrs) 10.0 0.020 <0.0001 
Creatinine (µmol/L) 7.7 0.007 0.0002 
LnPackyears  4.5 0.060 0.0001 
Diuretic (yes/no) 3.2 0.110 0.0006 
HbA1c (mmol/mol) 2.6 0.017 0.0026 
Whole model R2 = 0.56 
Type 2 diabetes 
Metformin (yes/no) 37.8 0.318 <0.0001 
Creatinine (µmol/L) 13.5 0.005 <0.0001 
NT-proBNP (AU) 9.4 0.145 <0.0001 
Age (yrs) 8.4 0.019 <0.0001 
HbA1c (mmol/mol) 4.1 0.006 <0.0001 
LnPackyears 2.6 0.038 0.0023 
Diuretic (yes/no) 2.3 0.068 0.0053 
Whole model R2 = 0.42 
All  
Metformin 42.8 0.323 <0.0001 
NT-proBNP (AU) 23.7 0.018 <0.0001 
Creatinine (µmol/L) 16.3 0.005 <0.0001 
Age (yrs) 15.1 0.017 <0.0001 
LnPackyears 7.2 0.054 <0.0001 
HbA1c (mmol/mol) 5.2 0.007 0.0001 
Diuretic (yes/no) 5.0 0.079 0.0001 
Diabetes (yes/no) 1.9 0.074 0.0129 
Whole model R2 = 0.51 
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